Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22406974 | 1.00 | MAPT (0.31) | MAPTHTT | |
| SCHEMBL5173738 | 1.00 | MAPT (0.31) | MAPTHTT | |
| SCHEMBL9083649 | 1.00 | MAPT (0.31) | MAPTHTT | |
| SCHEMBL10416083 | 1.00 | MAPT (0.31) | MAPTHTT | |
| SCHEMBL10416099 | 1.00 | MAPT (0.31) | MAPTHTT | |
| SCHEMBL5173742 | 1.00 | MAPT (0.31) | MAPTHTT | |
| SCHEMBL9726025 | 1.00 | MAPT (0.31) | MAPTHTT | |
| SCHEMBL9726023 | 0.87 | GAA (0.35) | — | |
| SCHEMBL11164271 | 0.87 | — | — | |
| SCHEMBL11164038 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3430013-B1 | CARBAPENEM COMPOUNDS | ORCHID PHARMA LTD (IN) | 2023-11-15 | — | — | EP | disclosed |
| EP-3430013-B1 | CARBAPENEM COMPOUNDS | ORCHID PHARMA LTD (IN) | 2023-11-15 | — | — | EP | disclosed |
| CN-109415365-B | Carbapenem compounds | 幽兰医药有限公司 | 2022-08-09 | — | — | CN | disclosed |
| US-11180504-B2 | Substituted carbapenems for the treatment of bacterial infections | ORCHID PHARMA LTD. (IN) | 2021-11-23 | — | — | US | disclosed |
| US-20200291029-A1 | CARBAPENEM COMPOUNDS | MERCK SHARP & DOHME CORP. | 2020-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11180504-B2 | Substituted carbapenems for the treatment of bacterial infections | SLC11A2, GSK3B, GSK3A | MAPT 4569/4885HTT 4879/4885 |
| US-20200291029-A1 | CARBAPENEM COMPOUNDS | GSK3B, GSK3A, GNE | MAPT 3938/4885HTT 4823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.